CNBX Pharmaceuticals CNBX

CNBX Pharmaceuticals Inc. is a clinical-stage company dedicated to the discovery, development, and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. The company’s primary focus is on advancing two lead drug candidates: Cannabics SR for the treatment of cancer anorexia cachexia syndrome (CACS) and RCC-33 for the treatment of colorectal cancer (CRC). CNBX Pharmaceuticals does not engage in manufacturing, distribution, or sales of products, instead planning to commercialize its drug candidates through licensing agreements or strategic partnerships with established pharmaceutical companies after successful clinical development.

CNBX Pharmaceuticals generates revenue through potential future licensing agreements, royalties, or milestone payments from partnerships with larger pharmaceutical companies upon successful development and regulatory approval of its drug candidates. The company does not currently have any commercial products on the market and therefore does not generate revenue from product sales. Revenue is expected to arise from the monetization of its intellectual property and clinical data through collaborations that leverage its research and development efforts in cannabinoid-based oncology therapies.

The company operates through the following segments:

• Cannabics SR: This segment focuses on the development of a sustained-release oral capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia cachexia syndrome (CACS). Cannabics SR is designed to provide a consistent and predictable release of active cannabinoids over a 6 to 8-hour duration, with onset of action within 30 to 40 minutes. The product candidate has demonstrated clinically significant weight increase in a peer-reviewed pilot study conducted by Dr. Gil Bar-Sela at Rambam Hospital in Haifa, Israel.

• RCC-33: This segment is dedicated to the development of an oral capsule containing a proprietary synthetic cannabinoid formulation for the treatment of colorectal cancer (CRC). RCC-33 has demonstrated the potential to reduce colorectal cancer tumor volume by over 30% in repeated in-vivo studies and is being developed as a first-in-class therapy for both neoadjuvant and adjuvant treatment settings. The segment includes ongoing preclinical studies to establish safety and efficacy parameters prior to planned Phase I/II(a) clinical trials in 2026.

CNBX Pharmaceuticals operates in the highly competitive biotechnology and pharmaceutical industry, specifically within the niche of cannabinoid-based oncology therapies. The company faces competition from established and emerging firms such as GW Pharmaceuticals PLC, Cannabis Science Inc., InMed Pharmaceuticals Inc., Emerald Bioscience Inc., Corbus Pharmaceuticals Holdings Inc., Zynerba Pharmaceuticals Inc., PharmaCyte Biotech Inc., Tetra Bio-Pharma Inc., and Cure Pharmaceutical Holding Corp., many of which are also developing cannabinoid-based treatments for cancer and related conditions. CNBX’s competitive advantages lie in its proprietary formulations, sustained-release technology, and focus on synergistic cannabinoid combinations, though it must overcome challenges related to limited financial resources, early-stage development, and the lengthy, costly regulatory approval process required by the FDA and other regulatory bodies.

CNBX Pharmaceuticals serves patients suffering from advanced cancer and cancer anorexia cachexia syndrome (CACS) through its Cannabics SR candidate, and patients with colorectal cancer (CRC) through its RCC-33 candidate. The company’s target customer base includes individuals undergoing cancer treatment who experience debilitating symptoms such as involuntary weight loss, muscle wasting, and reduced quality of life due to CACS, as well as those diagnosed with colorectal cancer seeking novel therapeutic options. While the company does not currently have commercial products, its future customers are expected to include hospitals, oncology clinics, and healthcare providers involved in cancer patient care.